Figure 3.
In vitro drug efficacy evaluation using KITWT, KITV560D, KITK642E and KITD816V PDX-derived cells. (A-D) Dose-response curve of imatinib, dasatinib, axitinib, nilotinib, ponatinib, sorafenib, and sunitinib in 72-h proliferation assays with KITWT, KITV560D, KITK642E and KITD816V PDX-derived cells. (E-F) Immunoblot analysis of KIT signaling in KITWT, KITV560D, KITK642E and KITD816V PDX-derived cells treated with imatinib, dasatinib, or ponatinib for 2 hours.